Myopathy induced by HMG-CoA reductase inhibitors in rabbits: A pathological, electrophysiological, and biochemical study

被引:82
作者
Nakahara, K [1 ]
Kuriyama, M [1 ]
Sonoda, Y [1 ]
Yoshidome, H [1 ]
Nakagawa, H [1 ]
Fujiyama, J [1 ]
Higuchi, I [1 ]
Osame, M [1 ]
机构
[1] Kagoshima Univ, Sch Med, Dept Internal Med 3, Kagoshima 890, Japan
关键词
HMG-CoA reductase inhibitor; rhabdomyolysis; pathology; myotonia; ubiquinone; mitochondrial enzyme; respiratory chain;
D O I
10.1006/taap.1998.8491
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A combination of electrophysiological, pathological, and biochemical studies were performed in myopathy induced by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Simvastatin (a lipophilic inhibitor) Or pravastatin (a hydrophilic inhibitor) were administered by gavage to rabbits. In Group I (simvastatin-treated group, 50 mg/kg/day for 4 weeks), four rabbits showed muscle necrosis and high serum creatine kinase (CK) levels, and all six rabbits showed electrical myotonia. In Group TI (pravastatin-treated group, 100 mg/kg/day for 4 weeks), fro rabbit showed either condition. In Group III (pravastatin-treated group, 200 mg/kg/day for 3 weeks plus 300 mg/kg/day for 3 weeks), one rabbit showed muscle necrosis and high serum CK level and two rabbits showed electrical myotonia. The pathological findings were muscle fiber necrosis and degeneration with increased acid phosphatase activity by light microscopy, autophagic vacuoles and mitochondrial swelling, and disruption and hypercontraction of myofibrils by electron microscopy. Ubiquinone content decreased in skeletal muscle by 22 to 36% in Group I, by 18 to 52% in Group II, and by 49 to 72% in Group III. However, mitochondrial enzyme activities of respiratory chain were normal in all groups. These results indicate that myopathy was not induced by a secondary dysfunction of mitochondrial respiration due to low ubiquinone levels. (C) 1998 Academic Press.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 32 条
[11]  
Hunninghake DB, 1992, Curr Opin Lipidol, V3, P22
[12]   CHOLESTEROL-LOWERING AGENT MYOPATHY (CLAM) [J].
LONDON, SF ;
GROSS, KF ;
RINGEL, SP .
NEUROLOGY, 1991, 41 (07) :1159-1160
[13]  
MALTESE WA, 1985, J BIOL CHEM, V260, P1524
[14]   EXTENDED CLINICAL SAFETY PROFILE OF LOVASTATIN [J].
MANTELL, G ;
BURKE, MT ;
STAGGERS, J .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (08) :B11-B15
[15]   EXPERIMENTAL SIMVASTATIN-INDUCED MYOPATHY IN RABBITS [J].
NAKAHARA, K ;
KURIYAMA, M ;
YOSHIDOME, H ;
NAGATA, K ;
NAGADO, T ;
NAKAGAWA, M ;
ARIMURA, K ;
HIGUCHI, I ;
OSAME, M .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1992, 113 (01) :114-117
[16]   CYTOSOLIC CA2+ INCREASE AND CELL-DAMAGE IN L6 RAT MYOBLASTS BY HMG-COA REDUCTASE INHIBITORS [J].
NAKAHARA, K ;
YADA, T ;
KURIYAMA, M ;
OSAME, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 202 (03) :1579-1585
[17]  
NORMAN DJ, 1988, NEW ENGL J MED, V318, P46
[18]   MUSCLE COENZYME-Q DEFICIENCY IN FAMILIAL MITOCHONDRIAL ENCEPHALOMYOPATHY [J].
OGASAHARA, S ;
ENGEL, AG ;
FRENS, D ;
MACK, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (07) :2379-2382
[19]   MITOCHONDRIAL-DNA DELETIONS IN INHERITED RECURRENT MYOGLOBINURIA [J].
OHNO, K ;
TANAKA, M ;
SAHASHI, K ;
IBI, T ;
SATO, W ;
YAMAMOTO, T ;
TAKAHASHI, A ;
OZAWA, T .
ANNALS OF NEUROLOGY, 1991, 29 (04) :364-369
[20]   MYOPATHY AND RHABDOMYOLYSIS ASSOCIATED WITH LOVASTATIN-GEMFIBROZIL COMBINATION THERAPY [J].
PIERCE, LR ;
WYSOWSKI, DK ;
GROSS, TP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (01) :71-75